Trial Search Results
A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver (NAFL) or Nonalcoholic Steatohepatitis (NASH)
TARGET-NASH is a longitudinal observational cohort study of patients being managed for NAFL or NASH in usual clinical practice. TARGET-NASH will create a research registry of patients with NAFL or NASH within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Stanford is currently accepting patients for this trial.
Target PharmaSolutions, Inc.
1. Adults and children (age 2 or older) being managed or treated for nonalcoholic fatty
liver disease. Diagnosis is based on the clinical judgement of the care provider.
1. Inability to provide written informed assent/consent
2. Simultaneous enrollment in another registry, study, or clinical trial where NASH
treatment outcomes are reported, except where approved or conducted as an adjunct
project of TARGET-NASH. If a participant elects to enroll in an interventional
clinical trial during their enrollment in TARGET-NASH, records submissions for the
participant will be put 'on hold' for the trial duration. When participation in the
trial is complete, records submissions for TARGET-NASH will resume.
Ages Eligible for Study
2 Years - N/A
Genders Eligible for Study